Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Patients with malignant pleural mesothelioma stage I-III who have undergone cytoreductive
surgery with curative intend consisting of extended pleurectomy / decortication (eP/D) with
or without hyperthermic intrathoracic chemoperfusion (HITOC) who will receive a maximum
treatment duration of 16 cycles (4 cycles of chemotherapy in both arms + 12 cycles
maintenance immunotherapy in treatment arm B). The main objective of the trial is
Time-to-next-treatment (TNT), as well as safety and tolerability.
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest